#78 - Immutep CEO Marc Voigt discusses the latest in immunotherapy for lung cancer

Michael Frazis interviews Marc Voigt, CEO of Imutep, discussing the challenges of lung cancer, the evolution of immunotherapy, and the innovative approaches Imutep is taking in cancer treatment. They explore clinical trial data, commercial opportunities, and advancements in autoimmune disease research, while also addressing the financial health and future directions of Immutep. 00:00 Introduction to Lung Cancer and Its Challenges 02:32 Understanding Treatment Options for Lung Cancer 05:22 The Evolution of Immunotherapy 08:00 Imutep's Innovative Approach to Cancer Treatment 10:39 Clinical Trials and Promising Data 13:47 Collaboration with Merck and Future Prospects 25:48 Clinical Trials and Efficacy Analysis 28:03 Commercial Opportunities in Oncology 31:15 Acquisition Trends in Biotech 31:38 Advancements in Head and Neck Cancer Treatment 37:32 Exploring Autoimmune Disease Treatments 45:26 Financial Strategies and Investment Priorities Keywords lung cancer, immunotherapy, clinical trials, cancer treatment, autoimmune diseases, Imutep, Keytruda, cancer research, market opportunities, healthcare innovation